ICU MEDICAL INC/DE
No enriched coverage for $ICUI in the last 7 days.
No SEC Form 4 filings for $ICUI in the last 30 days.
This article reports on an SEC Form 144 filing by ICU MEDICAL INC/DE (ICUI). The filing details a proposed sale of 2424 common shares with an aggregate market value of $297,933.84, acquired through the exercise of options under a registered plan. The purpose of the Form 144 is to provide notice of the proposed sale of securities under Rule 144 of the Securities Act of 1933.
ICU Medical (NASDAQ:ICUI) reported its Q1 2026 financial results, showing a 12% year-over-year revenue decline to $526 million due to the deconsolidation of its IV Solutions joint venture, but maintained 1% organic growth. The company exceeded earnings expectations with an adjusted EPS of $1.97 and saw strong performance in its Infusion Systems segment, while facing challenges from tariffs, logistics costs, and FDA review timelines. ICU Medical provided positive forward guidance for Q2 and Q3 2026, indicating expected sequential improvement.
Wall Street Zen downgraded ICU Medical (NASDAQ:ICUI) from "buy" to "hold." This comes after ICU Medical reported Q4 EPS of $1.91, exceeding estimates, but revenue of $535.9M missed expectations and was down 14.1% year-over-year. The medical instruments supplier has a mixed analyst outlook with an average rating of "Moderate Buy" and institutional ownership around 96%.
